Study aim: This clinical trial aims to assess the effect of propolis on clinical symptoms in patients with coronavirus. Design: This study is a double-blind, placebo-controlled, randomized phase 2 clinical trial evaluating the effect of propolis on clinical symptoms in patients with coronavirus. In this study, 80 eligible participants will be randomly assigned to either the intervention or the control group. The randomization sequence will be generated using a random-number table. Settings and conduct: In this study, patients with coronavirus will be recruited from the Al-Zahra hospital in Isfahan. Participants who meet entry criteria will be randomly assigned to the propolis group or the placebo group. The participant's assignment will be concealed from all participants and investigators, with the exception of the study pharmacist. Participants/Inclusion and exclusion criteria: The inclusion criteria are the age of 18 to 75 years, willingness to participate with written informed consent, and the diagnosis of coronavirus based on the PCR test. The exclusion criteria are the current use of warfarin, current use of propolis supplement, and presence of sensitivity to bee products. Intervention groups: Participants in the intervention group will receive an identical propolis tablet (containing 300 mg Iranian green propolis extract) three times a day for 2 weeks. Participants in the placebo group will receive an identical tablet placebo (containing 300 mg microcrystalline cellulose ) three times a day for 2 weeks. Main outcome variables: Respiratory Rate, Chest CT scan, High-sensitivity C-reactive protein, Erythrocyte Sedimentation Rate, Severity and number of coughs